Burnsville, MN, United States
Burnsville, MN, United States
SEARCH FILTERS
Time filter
Source Type

News Article | May 4, 2017
Site: www.businesswire.com

LISLE, Ill.--(BUSINESS WIRE)--CTS Corporation’s RF Sensor for particulate filters has been nominated by the AMA Association for Sensor and Measurement as a finalist for their 2017 Innovation Award. The RF Sensor is a new technology for directly monitoring and diagnosing the state of diesel and gasoline emission control systems on-board the vehicle using radio frequency (RF) technology. The AMA Association for Sensor and Measurement brings together technology companies which specialize in sensing and the measurement of physical, chemical, climatic, or other parameters. Presented this year for the 17th time, the AMA Innovation Award is among the most renowned prizes in sensor and measurement technology. CTS’ RF Sensor provides an alternative to conventional methods to meet on-board diagnostics (OBD) requirements for particulate filters through direct, and highly accurate, measurements of the filter’s state. Originally developed for diesel applications, particulate filters are now being implemented for gasoline vehicles to reduce soot emissions as well. CTS’ RF Sensor enables more efficient engine and emissions system operation by providing multiple sense functions in a single device, which simplifies and improves both the control and diagnostics of particulate filters. The winner for the 2017 Innovation Award will be announced during the opening ceremony of the SENSOR +TEST exhibition on May 30th, in Nuremburg, Germany. CTS (NYSE: CTS) is a leading designer and manufacturer of sensors, actuators and electronic components to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets. CTS manufactures products in North America, Europe and Asia.


News Article | May 16, 2017
Site: www.businesswire.com

LISLE, Ill.--(BUSINESS WIRE)--CTS Corporation (NYSE: CTS) has announced the acquisition of Noliac A/S; a designer and manufacturer of tape cast and bulk piezoelectric components, sensors and transducers. Headquartered in Denmark with manufacturing facilities in Denmark and the Czech Republic, Noliac serves OEMs in the aerospace & defense, test & measurement, medical and industrial markets. Founded in 1997, Noliac leverages twenty years of experience in piezoelectric multi-layer tape cast manufacturing to produce stacked actuators and other components. Since its founding, Noliac has expanded operations to also include piezoelectric bulk manufacturing processes and in-house design and production capabilities for sensors and transducers. “The acquisition of Noliac demonstrates CTS’ commitment to our strategy of investing in technologies that Sense, Connect and Move,” stated Kieran O’Sullivan, CEO of CTS Corporation. “In 2016 we acquired single crystal production capabilities to strengthen our piezoelectric product portfolio. By acquiring Noliac, we expand our tape cast manufacturing capabilities. This enables us to provide a more complete range of piezoelectric solutions to our customers, while growing our European presence and further diversifying our end market profile.” “On behalf of the team at Noliac, we are excited to join the CTS family,” stated Bjørn Andersen, CEO and founder of Noliac A/S. “CTS’ high volume production expertise for piezoelectric ceramics and single crystal products is a perfect fit for Noliac. This acquisition provides Noliac with the resources to continue to grow. We are looking forward to reaching the next level with CTS.” CTS (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and supplies these products to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets.


LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Concord Medical Services Holdings Ltd. (NYSE: CCM) as the Company announced on May 19, 2017, that its subsidiary, Meizhong Jiahe Hospital Management Corp. Ltd, previously known as CMS Hospital Management Co., Ltd, jointly with Guofu Huimei Investment Management Limited Partnership, has proposed to acquire Shanghai ProMed Cancer Center, LLC by purchasing existing, and subscribing for newly released, registered capital of ProMed. Post the acquisition, MHM will hold 31.64% of the equity interest in ProMed Cancer Center. Register with us now for your free membership and blog access at: One of Concord Medical Services Holdings' competitors within the Hospitals space, Community Health Systems, Inc. (NYSE: CYH), announced on May 01, 2017, its financial and operating results for the three months ended March 31, 2017. AWS will be initiating a research report on Community Health Systems in the coming days. Today, AWS is promoting its blog coverage on CCM; touching on CYH. Get all of our free blog coverage and more by clicking on the link below: This announcement is viewed as a critical point for the Company's long-term strategy of developing a specialized cancer hospital in China. Post the acquisition, ProMed will be the flagship cancer center under Meizhong Jiahe brand and will deliver an additional regional advantage, an independent medical institution license and high-end equipment. Additionally, the Company will upgrade the service procedure and clinical skills to offer best-in-class treatment. Concord Medical will enable quality management and talent training system by cooperating with prominent cancer treatment institutions across the world, by providing better cancer diagnosis and treatment. ProMed has a comprehensive portfolio of advanced medical equipment, such as linear accelerators, Cts, MRIs, Mo-target mammography, CDFI, and telepathology consultation systems. Located on the campus of Shanghai Ruijin Hospital, Luwan Brand, the cancer center offers a multitude of medical resources for the patients. Promed's outpatient cancer clinic offers medical services including diagnostic imaging, radiation oncology, medical oncology such as chemotherapy, targeted therapy, and immunization therapy to its patients. Additionally, ProMed is collaborating with multiple international cancer treatment institutions to enable better patient cure rate and life expectancy. ProMed will deliver high-end clinical tumor diagnosis and treatment services to public medical insured patients and business insured patients as well. Concord Medical is a leading specialty hospital management solution provider and operator of China's largest network of radiotherapy and diagnostic imaging centers. The Company currently operates through a network of 123 centers with 73 hospital partners across 52 cities and 25 provinces and administrative regions in China. Concord delivers radiotherapy and diagnostic imaging equipment in long-term collaboration with top-tier hospital in China and manages the operational end of these test centers. The Company acquired Concord Cancer Hospital, a private hospital in Singapore, April 2015 under an attempt to expand its high-end cancer hospital development strategy and oversea business extension. Concord Medical recently signed an agreement with Ion Beam Applications S.A., for the purchase, installation, and maintenance of proton theory which is scheduled to be installed at Beijing Proton Medical Center. The Beijing Medical Center is jointly developed by Concord Medical and China-Japan Friendship Hospital. IBA's proton theory has been used to treat more cancer patients that any other Company in the world. This extensive experience and knowledge of proton theory treatment have enabled IBA to ensure that more patients are able to get this highly accurate form of cancer treatment. In January 2016, the Company acquired 100% equity interest in Beijing Century Friendship and an additional 55% equity interest in Beijing Proton Medical Center with a total consideration of RMB 100.6 million and ultimately held 80% equity interest in Beijing Proton Medical Center. At the close of trading session on Friday, May 19, 2017, Concord Medical Services' stock price was marginally down by 0.72% to end the day at $4.16. A total volume of 10.58 thousand shares were exchanged during the session. The Company's share price has surged 15.88% in the past twelve months. Concord Medical's stock has a net market capital of $181.21 million as per Friday's last closing price. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Concord Medical Services Holdings Ltd. (NYSE: CCM) as the Company announced on May 19, 2017, that its subsidiary, Meizhong Jiahe Hospital Management Corp. Ltd, previously known as CMS Hospital Management Co., Ltd, jointly with Guofu Huimei Investment Management Limited Partnership, has proposed to acquire Shanghai ProMed Cancer Center, LLC by purchasing existing, and subscribing for newly released, registered capital of ProMed. Post the acquisition, MHM will hold 31.64% of the equity interest in ProMed Cancer Center. Register with us now for your free membership and blog access at: One of Concord Medical Services Holdings' competitors within the Hospitals space, Community Health Systems, Inc. (NYSE: CYH), announced on May 01, 2017, its financial and operating results for the three months ended March 31, 2017. AWS will be initiating a research report on Community Health Systems in the coming days. Today, AWS is promoting its blog coverage on CCM; touching on CYH. Get all of our free blog coverage and more by clicking on the link below: This announcement is viewed as a critical point for the Company's long-term strategy of developing a specialized cancer hospital in China. Post the acquisition, ProMed will be the flagship cancer center under Meizhong Jiahe brand and will deliver an additional regional advantage, an independent medical institution license and high-end equipment. Additionally, the Company will upgrade the service procedure and clinical skills to offer best-in-class treatment. Concord Medical will enable quality management and talent training system by cooperating with prominent cancer treatment institutions across the world, by providing better cancer diagnosis and treatment. ProMed has a comprehensive portfolio of advanced medical equipment, such as linear accelerators, Cts, MRIs, Mo-target mammography, CDFI, and telepathology consultation systems. Located on the campus of Shanghai Ruijin Hospital, Luwan Brand, the cancer center offers a multitude of medical resources for the patients. Promed's outpatient cancer clinic offers medical services including diagnostic imaging, radiation oncology, medical oncology such as chemotherapy, targeted therapy, and immunization therapy to its patients. Additionally, ProMed is collaborating with multiple international cancer treatment institutions to enable better patient cure rate and life expectancy. ProMed will deliver high-end clinical tumor diagnosis and treatment services to public medical insured patients and business insured patients as well. Concord Medical is a leading specialty hospital management solution provider and operator of China's largest network of radiotherapy and diagnostic imaging centers. The Company currently operates through a network of 123 centers with 73 hospital partners across 52 cities and 25 provinces and administrative regions in China. Concord delivers radiotherapy and diagnostic imaging equipment in long-term collaboration with top-tier hospital in China and manages the operational end of these test centers. The Company acquired Concord Cancer Hospital, a private hospital in Singapore, April 2015 under an attempt to expand its high-end cancer hospital development strategy and oversea business extension. Concord Medical recently signed an agreement with Ion Beam Applications S.A., for the purchase, installation, and maintenance of proton theory which is scheduled to be installed at Beijing Proton Medical Center. The Beijing Medical Center is jointly developed by Concord Medical and China-Japan Friendship Hospital. IBA's proton theory has been used to treat more cancer patients that any other Company in the world. This extensive experience and knowledge of proton theory treatment have enabled IBA to ensure that more patients are able to get this highly accurate form of cancer treatment. In January 2016, the Company acquired 100% equity interest in Beijing Century Friendship and an additional 55% equity interest in Beijing Proton Medical Center with a total consideration of RMB 100.6 million and ultimately held 80% equity interest in Beijing Proton Medical Center. At the close of trading session on Friday, May 19, 2017, Concord Medical Services' stock price was marginally down by 0.72% to end the day at $4.16. A total volume of 10.58 thousand shares were exchanged during the session. The Company's share price has surged 15.88% in the past twelve months. Concord Medical's stock has a net market capital of $181.21 million as per Friday's last closing price. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / May 22, 2017 / Active Wall St. blog coverage looks at the headline from Concord Medical Services Holdings Ltd. (NYSE: CCM) as the Company announced on May 19, 2017, that its subsidiary, Meizhong Jiahe Hospital Management Corp. Ltd, previously known as CMS Hospital Management Co., Ltd, jointly with Guofu Huimei Investment Management Limited Partnership, has proposed to acquire Shanghai ProMed Cancer Center, LLC by purchasing existing, and subscribing for newly released, registered capital of ProMed. Post the acquisition, MHM will hold 31.64% of the equity interest in ProMed Cancer Center. Register with us now for your free membership and blog access at: One of Concord Medical Services Holdings' competitors within the Hospitals space, Community Health Systems, Inc. (NYSE: CYH), announced on May 01, 2017, its financial and operating results for the three months ended March 31, 2017. AWS will be initiating a research report on Community Health Systems in the coming days. Today, AWS is promoting its blog coverage on CCM; touching on CYH. Get all of our free blog coverage and more by clicking on the link below: This announcement is viewed as a critical point for the Company's long-term strategy of developing a specialized cancer hospital in China. Post the acquisition, ProMed will be the flagship cancer center under Meizhong Jiahe brand and will deliver an additional regional advantage, an independent medical institution license and high-end equipment. Additionally, the Company will upgrade the service procedure and clinical skills to offer best-in-class treatment. Concord Medical will enable quality management and talent training system by cooperating with prominent cancer treatment institutions across the world, by providing better cancer diagnosis and treatment. ProMed has a comprehensive portfolio of advanced medical equipment, such as linear accelerators, Cts, MRIs, Mo-target mammography, CDFI, and telepathology consultation systems. Located on the campus of Shanghai Ruijin Hospital, Luwan Brand, the cancer center offers a multitude of medical resources for the patients. Promed's outpatient cancer clinic offers medical services including diagnostic imaging, radiation oncology, medical oncology such as chemotherapy, targeted therapy, and immunization therapy to its patients. Additionally, ProMed is collaborating with multiple international cancer treatment institutions to enable better patient cure rate and life expectancy. ProMed will deliver high-end clinical tumor diagnosis and treatment services to public medical insured patients and business insured patients as well. Concord Medical is a leading specialty hospital management solution provider and operator of China's largest network of radiotherapy and diagnostic imaging centers. The Company currently operates through a network of 123 centers with 73 hospital partners across 52 cities and 25 provinces and administrative regions in China. Concord delivers radiotherapy and diagnostic imaging equipment in long-term collaboration with top-tier hospital in China and manages the operational end of these test centers. The Company acquired Concord Cancer Hospital, a private hospital in Singapore, April 2015 under an attempt to expand its high-end cancer hospital development strategy and oversea business extension. Concord Medical recently signed an agreement with Ion Beam Applications S.A., for the purchase, installation, and maintenance of proton theory which is scheduled to be installed at Beijing Proton Medical Center. The Beijing Medical Center is jointly developed by Concord Medical and China-Japan Friendship Hospital. IBA's proton theory has been used to treat more cancer patients that any other Company in the world. This extensive experience and knowledge of proton theory treatment have enabled IBA to ensure that more patients are able to get this highly accurate form of cancer treatment. In January 2016, the Company acquired 100% equity interest in Beijing Century Friendship and an additional 55% equity interest in Beijing Proton Medical Center with a total consideration of RMB 100.6 million and ultimately held 80% equity interest in Beijing Proton Medical Center. At the close of trading session on Friday, May 19, 2017, Concord Medical Services' stock price was marginally down by 0.72% to end the day at $4.16. A total volume of 10.58 thousand shares were exchanged during the session. The Company's share price has surged 15.88% in the past twelve months. Concord Medical's stock has a net market capital of $181.21 million as per Friday's last closing price. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | May 19, 2017
Site: www.businesswire.com

LISLE, Ill.--(BUSINESS WIRE)--CTS Corporation (NYSE: CTS) announced the retirement of Lawrence Ciancia yesterday at its Annual Shareholders Meeting. Kieran O’Sullivan, Chairman and CEO, and Bob Profusek, CTS’ Lead Director, expressed their sincere gratitude to Mr. Ciancia for his many years of outstanding service. Mr. Ciancia served as a director of the Board over his nearly 27-year tenure, and at times as chairman and member of the Audit Committee and of the Nominating and Governance Committee. Mr. O’Sullivan stated, “On behalf of the entire Company and Board, I wish Larry a happy and healthy retirement.” CTS (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and supplies these products to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets.


LISLE, Ill.--(BUSINESS WIRE)--CTS Corporation (NYSE: CTS) will release earnings for the second quarter 2017 at approximately 8:00 a.m. (EDT) on Thursday, July 27, 2017. A conference call to discuss second quarter financial results with management is scheduled for Thursday, July 27, 2017 at 11:00 a.m. (EDT). The dial-in number for the U.S. is 888-490-2759 (719-457-2663, if calling from outside the U.S.). The passcode is 317965. There will be a replay of the conference call from 2:00 p.m. (EDT) on Thursday, July 27, 2017 through 2:00 p.m. (EDT) on Thursday, August 10, 2017. The telephone number for the replay is 888-203-1112 (719-457-0820, if calling from outside the U.S.). The replay passcode is 2589157. A live audio webcast of the conference call will be available and can be accessed directly from the Investors section of the website of CTS Corporation at www.ctscorp.com. CTS (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and supplies these products to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets.


LISLE, Ill.--(BUSINESS WIRE)--CTS Corporation’s RF Sensor for particulate filters has won the AMA Association for Sensor and Measurement’s 2017 Innovation Award. Presented this year for the 17th time, the AMA Innovation Award is among the most renowned prizes in sensor and measurement technology. “This year, 41 teams with first-rate developments competed for the AMA Innovation Award,” stated jury chair Professor Andreas Schütze from the Saarland University. “We were convinced by the development of the winning team with their solution to a very current topic, emission reduction and emission system control. The discussions held worldwide on this subject are also an indicator for the vast market relevance for such a CTS RF sensor.” CTS’ RF Sensor provides an alternative to conventional methods to meet on-board diagnostics (OBD) requirements for particulate filters through direct, and highly accurate, measurements of the filter’s state. Originally developed for diesel applications, particulate filters are now also being implemented for gasoline vehicles to reduce soot emissions. CTS’ RF Sensor enables more efficient engine and emissions system operation and control by providing multiple sense functions in a single device, which simplifies and improves both the control and diagnostics of particulate filters. CTS (NYSE: CTS) is a leading designer and manufacturer of sensors, actuators and electronic components to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets. CTS manufactures products in North America, Europe and Asia.


News Article | July 27, 2017
Site: www.businesswire.com

“We delivered mid-single digit organic sales growth,” said Kieran O’Sullivan, CEO of CTS Corporation. “Adjusted EPS grew 8% despite some one-time costs. The Noliac acquisition is another step in advancing our strategy, adding multilayer piezoelectric technology to our portfolio and expanding our capabilities in Europe.” Management reaffirms its prior guidance. Full year 2017 sales are expected to be in the range of $405 to $420 million, as management continues to monitor market conditions. Adjusted earnings per diluted share for 2017 are expected to be in the range of $1.12 to $1.22. As previously announced, the Company has scheduled a conference call at 11:00 a.m. (EDT) today to discuss the second quarter financial results. The dial-in number is 888-490-2759 (719-457-2663, if calling from outside the U.S.). The passcode is 317965. There will be a replay of the conference call from 2:00 p.m. (EDT) today through 2:00 p.m. (EDT) on Thursday, August 10, 2017. The telephone number for the replay is 888-203-1112 (719-457-0820, if calling from outside the U.S.). The replay passcode is 2589157. A live audio webcast of the conference call will be available and can be accessed directly from the Investors section of the website of CTS Corporation at www.ctscorp.com. CTS (NYSE: CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and supplies these products to OEMs in the aerospace, communications, defense, industrial, information technology, medical and transportation markets. This document contains statements that are, or may be deemed to be, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, any financial or other guidance, statements that reflect our current expectations concerning future results and events, and any other statements that are not based solely on historical fact. Forward-looking statements are based on management's expectations, certain assumptions and currently available information. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof and are based on various assumptions as to future events, the occurrence of which necessarily are subject to uncertainties. These forward-looking statements are made subject to certain risks, uncertainties and other factors, which could cause our actual results, performance or achievements to differ materially from those presented in the forward-looking statements. Many of these, and other, risks and uncertainties are discussed in further detail in Item 1A. of CTS’ Annual Report on Form 10-K. We undertake no obligation to publicly update our forward-looking statements to reflect new information or events or circumstances that arise after the date hereof, including market or industry changes. The following table reconciles GAAP diluted earnings per share to adjusted diluted earnings per share for the Company: The following table includes other financial information not presented in the preceding financial statements. The following table includes other financial information not presented in the preceding financial statements. Adjusted earnings per share is a non-GAAP financial measure. The most directly comparable GAAP financial measure is diluted earnings per share. CTS adjusts for these items because they are discrete events, which have a significant impact on comparable GAAP financial measures and could distort an evaluation of our normal operating performance. CTS uses an adjusted earnings per share measure to evaluate overall performance, establish plans and perform strategic analysis. Using this measure avoids distortion in the evaluation of operating results by eliminating the impact of events which are not related to normal operating performance. Because this measure is based on the exclusion or inclusion of specific items, they may not be comparable to measures used by other companies which have similar titles. CTS' management compensates for this limitation when performing peer comparisons by evaluating both GAAP and non-GAAP financial measures reported by peer companies. CTS believes that this measure is useful to its management, investors and stakeholders in that it: We recommend that investors consider both actual and adjusted measures in evaluating the performance of CTS with peer companies.


LOS ANGELES, May 26, 2017 /PRNewswire/ -- Is it possible to design a new concrete casting methodology, leveraging the precision and freedom of industrial robots? That was the question posed by Form Found Design when Joseph Sarafian and Ron Culver began their Fabric Forms research. They...


LEXINGTON, Mass. & ORLANDO, Fla.--(BUSINESS WIRE)--Imprivata®, the healthcare IT security company, and Connected Technology Solutions (CTS), today announced a partnership to enable positive patient identification at self-service registration kiosks. Imprivata PatientSecure® eliminates the need for providers and patients to input patient information manually by integrating with CTS kiosks to make the single patient identifier available through kiosk registration. According to the 2016 National Patient Misidentification Report from the Ponemon Institute, 63 percent of top-level U.S. healthcare executives and care providers say that the primary cause of patient misidentification is incorrect identification at the registration desk. To help eliminate patient identification errors at the source, Imprivata PatientSecure allows hospitals to identify patients through a biometric palm vein scan at CTS kiosks, rather than requiring manual input of patient information, verifying their medical information, co-pay collection, insurance validation, and more. “Since deploying our palm vein biometric identification platform, we have significantly reduced registration errors and lowered our duplicate medical record rate to 0.01 percent of our patient census, which is 80 times better than the national average,” said Craig Richardville, Chief Information & Analytics Officer at Carolinas Healthcare System. “Now that we’re able to integrate this technology directly into our registration kiosks, we expect increased improvement in our front-end patient registration process, which will further enhance our overall revenue cycle management operation and patient experience.” CTS leads the kiosk industry with purpose-built and specifically designed kiosk units for patient check-in. Embedding positive patient identification into CTS kiosks ensures accurate patient identification at check-in, and also improves insurance validation, collection of co-pays, and form fulfilment, addressing evolving patient needs while helping to drive new efficiencies in healthcare. “The use of biometric identification at registration kiosks is a great addition to our solutions and helps transform the entire registration and intake process, working directly with the Epic EHR,” said Marc Avallone, Vice President of Sales & Business Development at CTS. “Integrating Imprivata PatientSecure palm-vein biometrics with our kiosks has sped up the patient identification process and assures positive patient identification every time. This improves patient safety, overall registration throughput, and ultimately enhances the entire patient experience.” Imprivata PatientSecure is the positive patient identification platform for healthcare that eliminates patient misidentification at any point of entry or care and positively identifies patients to improve patient safety, increase revenue capture, and prevent identity theft. Beyond identification at registration, Imprivata PatientSecure helps hospitals to re-identify patients throughout their healthcare experience at points of care including medication administration, radiation oncology treatments, and blood transfusions. “Deep integrations with self-service kiosks, EHRs, and other digital health technologies are critical to ensuring positive patient identification at all points of care across the healthcare continuum,” said Justyna Evlogiadis, Senior Product Marketing Manager at Imprivata. “By partnering with CTS, we’re ensuring that patients are accurately identified and experience the best possible patient registration workflows, ultimately improving patient adoption of self-service kiosks as well as patient safety and revenue cycle performance.” The joint Imprivata and CTS solution is on display this week at the HIMSS17 Conference and Exhibition (February 20-22, 2017 in Orlando, Florida) in Imprivata booth #747 and CTS booth #1123. About Imprivata Imprivata®, the healthcare IT security company, provides healthcare organizations globally with a security and identity platform that delivers authentication management, fast access to patient information, secure communications, and positive patient identification. Imprivata enables care providers to securely and efficiently access, communicate, and transact patient health information to address critical compliance and security challenges while improving productivity and the patient experience. For more information, please visit www.imprivata.com. About Connected Technology Solutions (CTS) Connected Technology Solutions (CTS) is the healthcare industry’s #1 provider in patient check-in solutions. The CTS flagship patient check-in kiosk, the Patient Passport Express™ (PPE) is not only aesthetically pleasing to the eyes but features a full 40” range of vertical motion. This is the only fully compliant wheelchair-accessible patient check-in kiosk unit available in the U.S. The PPE’s are deployed across the United States, with over 200 million patient check-in transactions to date. Visit us at http://www.ctshealthcare.com for more information on how we can help you.

Loading Cts Inc. collaborators
Loading Cts Inc. collaborators